A novel α-enolase-targeted drug delivery system for high efficacy prostate cancer therapy

作者：Wang, Luyao; Qu, Mengke; Huang, Shiqi; Fu, Yu; Yang, Liuqing; He, Shanshan; Li, Lin; Zhang, Zhirong; Lin, Qing^*; Zhang, Ling^*

来源：Nanoscale, 2018, 10(28): 13673-13683.

DOI：10.1039/c8nr03297a

• PEPTIDE
• NANOPARTICLES
• DOXORUBICIN
• LIPOSOMES
• NANOMEDICINE
• PACLITAXEL
• METASTASIS
• CARCINOMA
• MARKER
• KI-67

Prostate cancer, one of the leading causes of disease and death in men all over the world, is challenging to treat. -Enolase, a multifunctional protein, is overexpressed on human prostate carcinoma cells, and thereby it is a potential target for treatment of prostate cancer. In the current study, the pHCT74 peptide was used to construct a kind of highly targeted liposome (pHCT74-lipo) loaded with doxorubicin (pHCT74-lipo-Dox), which specifically targeted -enolase on prostate tumour cells. Compared with liposomes without pHCT74 modification, pHCT74-lipo-Dox displayed a superior intracellular internalization with enhanced tumour cytotoxicity. In the in vivo study, pHCT74-lipo showed much higher tumour accumulation. In addition, loaded into pHCT74-lipo, doxorubicin demonstrated significantly improved anti-tumour activity on prostate tumour-bearing mice. These results suggest that the pHCT74 peptide has potential to be used in the development of a novel drug delivery system for targeted therapy against prostate cancer.

• 出版日期2018-7-28
• 单位四川大学